Woman Achieves Remarkable Recovery from Three Autoimmune Diseases via CAR T-Cell Therapy
A 47-year-old woman in Germany has achieved a near-normal life after receiving pioneering CAR T-cell therapy for three life-threatening autoimmune diseases: autoimmune haemolytic anaemia, immune thrombocytopenia, and antiphospholipid syndrome. Having suffered for over a decade and failed nine previous treatments, she required daily blood transfusions and permanent medication before the procedure at University Hospital Erlangen. The therapy, which involves engineering the patient’s T-cells to target and destroy rogue B-cells, successfully reset her immune system. Within weeks, all three conditions responded, allowing her to enter treatment-free remission for 14 months. This case marks a world first, demonstrating the potential of CAR T-cell therapy, previously used mainly for cancers, to treat complex autoimmune disorders. While the patient retains minor health markers attributed to prior treatments, her quality of life has significantly improved. Scientists emphasize the need for further clinical trials to determine the durability of this immune reset and its applicability to other autoimmune conditions, offering new hope for patients with refractory diseases.
Wire timeline
Woman Achieves Remarkable Recovery from Three Autoimmune Diseases via CAR T-Cell Therapy
A 47-year-old woman in Germany has achieved a near-normal life after receiving pioneering CAR T-cell therapy for three life-threatening autoimmune diseases: autoimmune haemolytic anaemia, immune thrombocytopenia, and antiphospholipid syndrome. Having suffered for over a decade and failed nine previous treatments, she required daily blood transfusions and permanent medication before the procedure at University Hospital Erlangen. The therapy, which involves engineering the patient’s T-cells to target and destroy rogue B-cells, successfully reset her immune system. Within weeks, all three conditions responded, allowing her to enter treatment-free remission for 14 months. This case marks a world first, demonstrating the potential of CAR T-cell therapy, previously used mainly for cancers, to treat complex autoimmune disorders. While the patient retains minor health markers attributed to prior treatments, her quality of life has significantly improved. Scientists emphasize the need for further clinical trials to determine the durability of this immune reset and its applicability to other autoimmune conditions, offering new hope for patients with refractory diseases.
The Guardian